文献速递肥胖与代谢综合征糖尿病

生长激素对普拉德-威利综合征年轻成人的有益作用:一项为期2年的交叉试验

Beneficial Effects of GH in Young Adults With Prader-Willi Syndrome: A 2-Year Crossover Trial.
PubMed 文献 · J Clin Endocrinol Metab · 2016-08-23

这项为期2年、随机、双盲、安慰剂对照交叉研究在27名已达成成年身高的普拉德-威利综合征年轻成人中比较生长激素(0.67 mg/m2·d)与安慰剂对体成分的影响。安慰剂期间脂肪量相对增加21.5%(P<.001);与安慰剂相比,生长激素治疗使脂肪量降低2.9 kg(P=.004)、瘦体重增加1.5 kg(P=.005),无生长激素相关不良事件。结论认为继续生长激素治疗可维持改善的体成分且无安全性担忧。

要点

  • 安慰剂期间脂肪量相对增加21.5%(P<.001)。
  • 与安慰剂相比,生长激素使脂肪量降低2.9 kg(P=.004)、瘦体重增加1.5 kg(P=.005)。
  • 未发生生长激素相关不良事件。

核心结论

  • 已达成成年身高的普拉德-威利综合征年轻成人继续生长激素治疗可获益,生长激素维持改善的体成分且无安全性担忧。

研究设计与样本

  • 为期2年、随机、双盲、安慰剂对照交叉研究,按性别和体重指数分层,纳入27名普拉德-威利综合征年轻成人,在荷兰普拉德-威利综合征参考中心进行。
  • 交叉干预为生长激素(0.67 mg/m2·d)与安慰剂,各持续1年。

主要发现

  • 安慰剂期间脂肪量相对增加21.5%(P<.001)。
  • 与安慰剂相比,生长激素治疗使脂肪量降低2.9 kg(P=.004),相对变化为脂肪量降低17.3%。
  • 与安慰剂相比,生长激素治疗使瘦体重增加1.5 kg(P=.005),相对变化为瘦体重增加3.5%。
  • 与安慰剂相比,生长激素治疗期间四肢和躯干脂肪百分比均更低(相对变化分别为增加17.3%和增加15.6%;P<.001和P=.007)。
  • 未发生生长激素相关不良事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Patients with Prader-Willi syndrome (PWS) are severely at risk to develop morbid obesity, diabetes mellitus type 2, and cardiovascular disease, leading to high mortality. They have an increased fat mass (FM) and decreased lean body mass (LBM). During childhood, GH treatment counteracts the natural course of increasing obesity. Discontinuation of GH treatment at attainment of adult height (AH) might deteriorate their improved clinical condition, whereas continuation might benefit them. OBJECTIVE: To investigate the effects of GH versus placebo on body composition in young adults with PWS who were GH treated for many years during childhood and had attained AH. DESIGN: Two-year, randomized, double-blind, placebo-controlled crossover study with stratification for gender and body mass index in 27 young adults with PWS. SETTING: PWS Reference Center in The Netherlands. INTERVENTION: Crossover intervention with GH (0.67 mg/m2 · d) and placebo, both during 1 year. MAIN OUTCOME MEASURES: Body composition, measured by dual-energy x-ray absorptiometry. RESULTS: During placebo, FM increased (relative change +21.5%; P < .001). Compared with placebo, GH treatment resulted in lower FM (-2.9 kg; P = .004) and higher LBM (+1.5 kg; P = .005), representing relative changes of -17.3% FM and +3.5% LBM. Both limb and trunk FM percentage were lower during GH versus placebo (relative change +17.3% and +15.6%; P < .001 and P = .007, respectively). No GH-related adverse events occurred. CONCLUSIONS: GH-treated young adults with PWS who have attained AH benefit from continuation of GH treatment. FM increases during placebo, whereas GH versus placebo results in lower FM and higher LBM. Thus, GH treatment maintains the improved body composition without safety concerns.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Kuppens RJ, Bakker NE, Siemensma EP, et al. Beneficial Effects of GH in Young Adults With Prader-Willi Syndrome: A 2-Year Crossover Trial. J Clin Endocrinol Metab. 2016. PMID: 27552545

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。